MNCs Eye Generics Buys To Enter Growing Southeast Asia Markets
This article was originally published in PharmAsia News
Making generic pharmaceuticals have become a major tool for foreign drug makers to get access to emerging markets in Southeast Asia as those markets outstrip the developed world in growth rates. Many multinationals are seeing their chances of growth more limited in developed markets, so they look to generics as a way to diversify. Emerging markets are expected to grow three times as fast as Western markets, by 13 percent a year, and account for 40 percent of the global drug market by 2020. The proposed acquisition of India's Ranbaxy Laboratories by Japan's Daiichi-Sankyo is cited by analysts as indicative of interest in the developing world. (Click here for more
You may also be interested in...
Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.